MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the...
This is not a financial advice! Entry above 7.0 Most info on the chart. Trade carefully!
MGNX = I propose one of the most winning and repetitive chart schemes, 7 times it behaved from the long-term rising lows and when the market was at the lows ... THE BEST RISK RETURN TO BET to get a 10-15 x return sometimes this is it ... BE CAREFUL AND ASSEMBLE IT .. as soon as the volumes enter ... you risk with little to have a very high yield .. Good...
A head and shoulder pattern can be seen from March - Mid June in a 3 Hour Chart. After that date, there was a down trend.
Macrogenics (MGNX, $28.87) was one of top quarterly gainers, jumping +433.64% to $28.87 per share. Tickeron A.I.dvisor analyzed 379 stocks in the Biotechnology Industry over the last three months, and discovered that 352 of them (92.98%) charted an Uptrend while 27 of them (7.02%) trended down. Tickeron A.I.dvisor found 287 similar cases when MGNX's price went up...
Contextual immersion trading strategy idea. MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than...
---MACROGENICS INC--- Weekly Chart Analyse- >>>Price is moviving into a DownChanel...And as u can see it's testing now the Upper Wall of this DownChannel...<<<
MGNX: MacroGenics, Inc. 2019-05-15 17:07:27 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer - GlobeNewswire
Afterhours Macrogenics Inc has announced Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer. This has resulted in a 15% jump in price on high volume, we will looking for continuation tomorrow, this could be a flyer. Company Profile MacroGenics, Inc. is a clinical-stage biopharmaceutical company,...
Will the lower trendline hold this time?
MGNX running within a downward channel & now seems reversing from the down channel line. It also seems forming a head & shoulder & now turning upward to form the second shoulder. Both way it looks bullish now. We think it will be a good long from preset price to 24 area. You can check detailed analysis on MGNX in the trading room/ Executive summary link...
Dead cat bounce possible followed by a swing low to target $17